This is a case report of a 68-year-old man with hepatocellular carcinoma (HCC) accompanied by hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu disease, and hepatic vascular malformation. HHT is an autosomal dominant disorder of the fibrovascular tissue that is characterized by recurrent epistaxis, mucocutaneous telangiectasias, and visceral arteriovenous malformations. HHT is caused by mutation of the genes involved in the signaling pathway of transforming growth factor-β, which plays an important role in the formation of vascular endothelia. Hepatic involvement has been reported as occurring in 30-73% of patients with HHT. However, symptomatic liver involvement is quite rare, and the representative clinical presentations of HHT in hepatic involvement are high-output heart failure, portal hypertension, nodular regenerative hyperplasia, and symptoms of biliary ischemia. Some cases of HCC in association with HHT have been reported, but are very rare. We present herein the characteristic radiologic and genetic findings of HHT that was diagnosed during the evaluation and treatment of HCC. (Korean J Hepatol 2011;17:313-318)
INTRODUCTION
Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu disease, is an autosomal dominant multiorgan disorder caused by a genetic defect encoding a protein that binds transforming growth factor, which results in abnormal vascular remodeling in the form of fibrovascular dysplasia with multiple telangiectasias. 1 HHT is caused by mutations in one of two genes that have led to its subclassification into type 1 or 2 disease in most cases. HHT type 1 disease, the disease-causing gene is located on chromosome 9, encoding endoglin (ENG). 2 In HHT type 2, the diseasecausing gene is located on chromosome 12, encoding activin receptor-like kinase 1 (ACVRL1). 3 HHT is characterized by the classic triad of mucocutaneous telangiectasias, recurrent epistaxis, and familial occurrence. 4 Multiple telangiectases consisting of thin-walled, dilated vascular channels with arteriovenous malformations may involve mucocutaneous tissue, gastrointestinal tract including the liver, lung, and brain. 5 The condition usually manifests in adults with epistaxis, hemoptysis, or both, and hepatic involvement is typically diagnosed 10-20 years after the first telangiectasias appear. 6, 7 The diagnosis of HHT is established when any three of the following criteria are present: (1) spontaneous and recurrent epistaxis; (2) multiple telangiectasias at characteristic sites, including lips, oral cavity, fingers, and nose; (3) presence of internal lesions such as gastrointestinal telangiectasia, pulmonary, Figure 1 . Typical splinter-like telangiectasias on the patient's arm (A), trunk (B), and midbody of the stomach (C). 
CASE REPORT
A 68-year-old man was referred for evaluation of a involvement was confirmed by the results of genetic study.
He is waiting for deceased donor liver transplantation for the treatment of HCC.
DISCUSSION
HHT or Osler-Weber-Rendu disease is a rare systemic fibrovascular dysplasia with autosomal dominant transmission, characterized by recurrent epistaxsis, mucocutaneous telangiectasis, and visceral AVMs. 1 It has an estimated prevalence of 1 in 5,000-10,000. Recurrent epistaxis is often the first and most common manifestation. 4 The dilated post capillary venule fuses with an arteriole bypassing the capillary system and resulting in an arterio-venous communication. HHT is caused by the mutation of the genes involved in the transforming growth factor-β signaling pathway which plays an important role in the formation of vascular endothelium. The combination of fibrotic telangiectases and nodular regenerative hyperplasia makes it hard to diagnose true hepatic mass lesions.
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The LDCT can demonstrate an enlarged hepatic artery, arteriovenous shunt, and early draining hepatic vein in the liver. 12, 13 Hepatic arteriography can be the best method of screening to characterize the liver vascular malformations.
The diagnosis of HCC is not easy in the background of the liver involved by HHT, because typical arterial enhancement and delayed washout pattern of HCC in dynamic CT scan could be masked by widespread AVMs and focal nodular hyperplasia common in HHT. 10 In our case, the diagnosis of HCC was possible due to typical radiologic features and 16 However, the presence of AVMs due to HHT could be an important barrier of effective TACE because blockade at feeding vessel in tumor is frequently impossible due to presence of AVMs. Usually the intrahepatic biliary tree obtains nearly all of its blood from the hepatic artery, so the presence of natural shunt from the hepatic artery to the hepatic or portal vein will result in biliary ischemia. 17 In this situation, the hepatic artery embolization might be a quite risky procedure. 3 In this case, three sessions of TACE were performed for the treatment of HCC, but those were ineffective and more severe deterioration of liver function was observed after TACE.
No treatment is recommended for HHT patients with asymptomatic liver involvement. In HHT patients with symptomatic liver disease, treatment can be divided into symptomatic treatment for the specific complications and management aimed at reducing the shunt by surgical ligation or transarterial embolization. 3 However, the hepatic artery embolization/ligation should be considered mainly in nontransplant candidate who failed maximal medical therapy due to the risk of necrotizing cholangitis and liver failure.
Orthotopic liver transplantation has been proposed as the only definitive curative option for the symptomatic liver involvement in HHT. 18 In conclusion, the diagnosis of HCC in the liver involved by HHT can be difficult due to its vascular malformation and regenerative nodular hyperplasia. TACE is ineffective in patients with HCC associated with HHT, therefore liver transplantation should be considered as the first-line treatment modality. We report here a case of HHT, presenting with HCC which developed in the background of multiple intrahepatic AVMs.
